The NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer continued to show a tolerable safety profile in a recent analysis.
Additional supportive data from stage 2a of a pivotal study of the NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer confirm the initial findings showing that the treatment modality was safe and effective, according to MagForce AG who is responsible for developing the system.1
Results were taken from a 10-patient cohort showing that only minimal treatment-related adverse effects and a tolerable safety profile were reported.